ReP USP - Resultado da busca

Artigo de periodico
Efficacy of dapagliflozin in black versus white patients with heart failure and reduced ejection fraction (2022)
Docherty, Kieran F; Ogunniyi, Modele O; Anand, Inder S; Desai, Akshay S; Diez, Mirta; Howlett, Jonathan G; Nicolau, Jose Carlos ; O'meara, Eileen; Verma, Subodh; Inzucchi, Silvio E
Source: Jacc-heart failure. Unidade: FM
Subjects: INSUFICIÊNCIA CARDÍACA, FÁRMACOS SINTÉTICOS, MORTALIDADE HOSPITALAR
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
DOCHERTY, Kieran F et al. Efficacy of dapagliflozin in black versus white patients with heart failure and reduced ejection fraction. Jacc-heart failure, v. 10, n. 1, p. 52-64, 2022Tradução . . Disponível em: https://doi.org/10.1016/j.jchf.2021.08.006. Acesso em: 09 nov. 2024.
APA
Docherty, K. F., Ogunniyi, M. O., Anand, I. S., Desai, A. S., Diez, M., Howlett, J. G., et al. (2022). Efficacy of dapagliflozin in black versus white patients with heart failure and reduced ejection fraction. Jacc-heart failure, 10( 1), 52-64. doi:10.1016/j.jchf.2021.08.006
NLM
Docherty KF, Ogunniyi MO, Anand IS, Desai AS, Diez M, Howlett JG, Nicolau JC, O'meara E, Verma S, Inzucchi SE. Efficacy of dapagliflozin in black versus white patients with heart failure and reduced ejection fraction [Internet]. Jacc-heart failure. 2022 ; 10( 1): 52-64.[citado 2024 nov. 09 ] Available from: https://doi.org/10.1016/j.jchf.2021.08.006
Vancouver
Docherty KF, Ogunniyi MO, Anand IS, Desai AS, Diez M, Howlett JG, Nicolau JC, O'meara E, Verma S, Inzucchi SE. Efficacy of dapagliflozin in black versus white patients with heart failure and reduced ejection fraction [Internet]. Jacc-heart failure. 2022 ; 10( 1): 52-64.[citado 2024 nov. 09 ] Available from: https://doi.org/10.1016/j.jchf.2021.08.006
Artigo de periodico
Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19 (2021)
Lawler, Patrick R; Golighe, Ewan C; Berge, Jeffrey S; Neal, Matthew D; Mcverry, Bryan J; Nicolau, Jose Carlos ; Gong, Michelle N; Carrier, Marc; Rosenson, Robert S; Reynolds, Harmony R
Source: New england journal of medicine. Unidade: FM
Subjects: COVID-19, TROMBOSE, ANTICOAGULANTES, PREVENÇÃO DE DOENÇA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
LAWLER, Patrick R et al. Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19. New england journal of medicine, v. 385, n. 9, p. 790-802, 2021Tradução . . Disponível em: https://doi.org/10.1056/NEJMoa2105911. Acesso em: 09 nov. 2024.
APA
Lawler, P. R., Golighe, E. C., Berge, J. S., Neal, M. D., Mcverry, B. J., Nicolau, J. C., et al. (2021). Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19. New england journal of medicine, 385( 9), 790-802. doi:10.1056/NEJMoa2105911
NLM
Lawler PR, Golighe EC, Berge JS, Neal MD, Mcverry BJ, Nicolau JC, Gong MN, Carrier M, Rosenson RS, Reynolds HR. Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19 [Internet]. New england journal of medicine. 2021 ; 385( 9): 790-802.[citado 2024 nov. 09 ] Available from: https://doi.org/10.1056/NEJMoa2105911
Vancouver
Lawler PR, Golighe EC, Berge JS, Neal MD, Mcverry BJ, Nicolau JC, Gong MN, Carrier M, Rosenson RS, Reynolds HR. Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19 [Internet]. New england journal of medicine. 2021 ; 385( 9): 790-802.[citado 2024 nov. 09 ] Available from: https://doi.org/10.1056/NEJMoa2105911
Artigo de periodico
Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19 (2021)
Goligher, Ewan C; Bradbury, Charlotte A; Mcverry, Bryan J; Lawler, Patrick R; Berger, Jeffrey S; Gong, Michelle N; Carrier, Marc; Reynolds, Harmony R; Kumar, Anand; Nicolau, Jose Carlos
Source: New england journal of medicine. Unidade: FM
Subjects: COVID-19, TROMBOSE, ANTICOAGULANTES
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
GOLIGHER, Ewan C et al. Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19. New england journal of medicine, v. 385, n. 9, p. 777-789, 2021Tradução . . Disponível em: https://doi.org/10.1056/NEJMoa2103417. Acesso em: 09 nov. 2024.
APA
Goligher, E. C., Bradbury, C. A., Mcverry, B. J., Lawler, P. R., Berger, J. S., Gong, M. N., et al. (2021). Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19. New england journal of medicine, 385( 9), 777-789. doi:10.1056/NEJMoa2103417
NLM
Goligher EC, Bradbury CA, Mcverry BJ, Lawler PR, Berger JS, Gong MN, Carrier M, Reynolds HR, Kumar A, Nicolau JC. Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19 [Internet]. New england journal of medicine. 2021 ; 385( 9): 777-789.[citado 2024 nov. 09 ] Available from: https://doi.org/10.1056/NEJMoa2103417
Vancouver
Goligher EC, Bradbury CA, Mcverry BJ, Lawler PR, Berger JS, Gong MN, Carrier M, Reynolds HR, Kumar A, Nicolau JC. Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19 [Internet]. New england journal of medicine. 2021 ; 385( 9): 777-789.[citado 2024 nov. 09 ] Available from: https://doi.org/10.1056/NEJMoa2103417
Artigo de periodico
Evolocumab in pediatric heterozygous familial hypercholesterolemia (2020)
Santos Filho, Raul Dias dos ; Ruzza, Andrea; Hovingh, G. Kees; Wiegman, Albert; Mach, Francois; Kurtz, Christopher E; Hamer, Andrew; Bridges, Ian; Bartuli, Andrea; Bergeron, Jean
Source: New england journal of medicine. Unidade: FM
Subjects: ADOLESCÊNCIA, ANTICORPOS MONOCLONAIS, COLESTEROL, MÉTODO DUPLO-CEGO, ESTATINAS, LIPÍDEOS, RESULTADO DE TRATAMENTO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SANTOS FILHO, Raul Dias dos et al. Evolocumab in pediatric heterozygous familial hypercholesterolemia. New england journal of medicine, v. 383, n. 14, p. 1317-1327, 2020Tradução . . Disponível em: https://doi.org/10.1056/NEJMoa2019910. Acesso em: 09 nov. 2024.
APA
Santos Filho, R. D. dos, Ruzza, A., Hovingh, G. K., Wiegman, A., Mach, F., Kurtz, C. E., et al. (2020). Evolocumab in pediatric heterozygous familial hypercholesterolemia. New england journal of medicine, 383( 14), 1317-1327. doi:10.1056/NEJMoa2019910
NLM
Santos Filho RD dos, Ruzza A, Hovingh GK, Wiegman A, Mach F, Kurtz CE, Hamer A, Bridges I, Bartuli A, Bergeron J. Evolocumab in pediatric heterozygous familial hypercholesterolemia [Internet]. New england journal of medicine. 2020 ; 383( 14): 1317-1327.[citado 2024 nov. 09 ] Available from: https://doi.org/10.1056/NEJMoa2019910
Vancouver
Santos Filho RD dos, Ruzza A, Hovingh GK, Wiegman A, Mach F, Kurtz CE, Hamer A, Bridges I, Bartuli A, Bergeron J. Evolocumab in pediatric heterozygous familial hypercholesterolemia [Internet]. New england journal of medicine. 2020 ; 383( 14): 1317-1327.[citado 2024 nov. 09 ] Available from: https://doi.org/10.1056/NEJMoa2019910
Artigo de periodico
Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial (2020)
Coleman, Robert; Finkelstein, Dianne M; Barrios, Carlos; Martin, Miguel; Iwata, Hiroji; Hegg, Roberto; Glaspy, John; Perianez, Alvaro Montano; Tonkin, Katia; Deleu, Ines
Source: Lancet oncology. Unidade: FM
Subjects: NEOPLASIAS MAMÁRIAS, QUIMIOTERAPIA ADJUVANTE, ANTICORPOS MONOCLONAIS, ENSAIO CLÍNICO CONTROLADO RANDOMIZADO, NEOPLASIAS ÓSSEAS, METÁSTASE NEOPLÁSICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
COLEMAN, Robert et al. Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial. Lancet oncology, v. 21, n. 1, p. 60-72, 2020Tradução . . Disponível em: https://doi.org/10.1016/S1470-2045(19)30687-4. Acesso em: 09 nov. 2024.
APA
Coleman, R., Finkelstein, D. M., Barrios, C., Martin, M., Iwata, H., Hegg, R., et al. (2020). Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial. Lancet oncology, 21( 1), 60-72. doi:10.1016/S1470-2045(19)30687-4
NLM
Coleman R, Finkelstein DM, Barrios C, Martin M, Iwata H, Hegg R, Glaspy J, Perianez AM, Tonkin K, Deleu I. Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial [Internet]. Lancet oncology. 2020 ; 21( 1): 60-72.[citado 2024 nov. 09 ] Available from: https://doi.org/10.1016/S1470-2045(19)30687-4
Vancouver
Coleman R, Finkelstein DM, Barrios C, Martin M, Iwata H, Hegg R, Glaspy J, Perianez AM, Tonkin K, Deleu I. Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial [Internet]. Lancet oncology. 2020 ; 21( 1): 60-72.[citado 2024 nov. 09 ] Available from: https://doi.org/10.1016/S1470-2045(19)30687-4
Artigo de periodico
Long-Term Evolocumab in Patients With Familial Hypercholesterolemia (2020)
Santos Filho, Raul Dias dos ; Stein, Evan A.; Hovingh, G. Kees; Blom, Dirk J; Soran, Handrean; Watts, Gerald F; Lopez, J. Antonio G; Bray, Sarah; Kurtz, Christopher E; Hamer, Andrew W
Source: Journal of the american college of cardiology. Unidade: FM
Subjects: HIPERCOLESTEROLEMIA, ANTICORPOS MONOCLONAIS, ENZIMAS PROTEOLÍTICAS, ANTIMETABÓLITOS, RESULTADO DE TRATAMENTO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SANTOS FILHO, Raul Dias dos et al. Long-Term Evolocumab in Patients With Familial Hypercholesterolemia. Journal of the american college of cardiology, v. 75, n. 6, p. 565-574, 2020Tradução . . Disponível em: https://doi.org/10.1016/j.jacc.2019.12.020. Acesso em: 09 nov. 2024.
APA
Santos Filho, R. D. dos, Stein, E. A., Hovingh, G. K., Blom, D. J., Soran, H., Watts, G. F., et al. (2020). Long-Term Evolocumab in Patients With Familial Hypercholesterolemia. Journal of the american college of cardiology, 75( 6), 565-574. doi:10.1016/j.jacc.2019.12.020
NLM
Santos Filho RD dos, Stein EA, Hovingh GK, Blom DJ, Soran H, Watts GF, Lopez JAG, Bray S, Kurtz CE, Hamer AW. Long-Term Evolocumab in Patients With Familial Hypercholesterolemia [Internet]. Journal of the american college of cardiology. 2020 ; 75( 6): 565-574.[citado 2024 nov. 09 ] Available from: https://doi.org/10.1016/j.jacc.2019.12.020
Vancouver
Santos Filho RD dos, Stein EA, Hovingh GK, Blom DJ, Soran H, Watts GF, Lopez JAG, Bray S, Kurtz CE, Hamer AW. Long-Term Evolocumab in Patients With Familial Hypercholesterolemia [Internet]. Journal of the american college of cardiology. 2020 ; 75( 6): 565-574.[citado 2024 nov. 09 ] Available from: https://doi.org/10.1016/j.jacc.2019.12.020
Artigo de periodico
Muscle mass, muscle strength, and functional capacity in patients with heart failure of Chagas disease and other aetiologies (2020)
Fonseca, Guilherme Wesley Peixoto da; Macedo, Tania Garfias; Ebner, Nicole; Santos, Marcelo Rodrigues dos; Souza, Francis Ribeiro de; Mady, Charles ; Guerra, Liliam Takayama ; Pereira, Rosa Maria Rodrigues ; Doehner, Wolfram; Anker, Stefan D; Negrão, Carlos Eduardo
Source: Esc heart failure. Unidades: FM, EEFE
Subjects: ENVELHECIMENTO, DOENÇA DE CHAGAS, INSUFICIÊNCIA CARDÍACA, COMPLICAÇÕES, EPIDEMIOLOGIA, FORÇA MUSCULAR, TESTOSTERONA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
FONSECA, Guilherme Wesley Peixoto da et al. Muscle mass, muscle strength, and functional capacity in patients with heart failure of Chagas disease and other aetiologies. Esc heart failure, v. 7, n. 5, p. 3086-3094, 2020Tradução . . Disponível em: https://doi.org/10.1002/ehf2.12936. Acesso em: 09 nov. 2024.
APA
Fonseca, G. W. P. da, Macedo, T. G., Ebner, N., Santos, M. R. dos, Souza, F. R. de, Mady, C., et al. (2020). Muscle mass, muscle strength, and functional capacity in patients with heart failure of Chagas disease and other aetiologies. Esc heart failure, 7( 5), 3086-3094. doi:10.1002/ehf2.12936
NLM
Fonseca GWP da, Macedo TG, Ebner N, Santos MR dos, Souza FR de, Mady C, Guerra LT, Pereira RMR, Doehner W, Anker SD, Negrão CE. Muscle mass, muscle strength, and functional capacity in patients with heart failure of Chagas disease and other aetiologies [Internet]. Esc heart failure. 2020 ; 7( 5): 3086-3094.[citado 2024 nov. 09 ] Available from: https://doi.org/10.1002/ehf2.12936
Vancouver
Fonseca GWP da, Macedo TG, Ebner N, Santos MR dos, Souza FR de, Mady C, Guerra LT, Pereira RMR, Doehner W, Anker SD, Negrão CE. Muscle mass, muscle strength, and functional capacity in patients with heart failure of Chagas disease and other aetiologies [Internet]. Esc heart failure. 2020 ; 7( 5): 3086-3094.[citado 2024 nov. 09 ] Available from: https://doi.org/10.1002/ehf2.12936
Artigo de periodico
Evolocumab in HIV-Infected Patients With Dyslipidemia Primary Results of the Randomized, Double-Blind BEIJERINCK Study (2020)
Boccara, Franck; Kumar, Princy N; Caramelli, Bruno ; Calmy, Alexandra; Lopez, J. Antonio G; Bray, Sarah; Cyrille, Marcoli; Rosenson, Robert S
Source: Journal of the american college of cardiology. Unidade: FM
Subjects: ESTATINAS, COLESTEROL, DOENÇAS CARDIOVASCULARES, ANTICORPOS MONOCLONAIS, DISLIPIDEMIAS, HIV
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BOCCARA, Franck et al. Evolocumab in HIV-Infected Patients With Dyslipidemia Primary Results of the Randomized, Double-Blind BEIJERINCK Study. Journal of the american college of cardiology, v. 75, n. 20, p. 2570-2584, 2020Tradução . . Disponível em: https://doi.org/10.1016/j.jacc.2020.03.025. Acesso em: 09 nov. 2024.
APA
Boccara, F., Kumar, P. N., Caramelli, B., Calmy, A., Lopez, J. A. G., Bray, S., et al. (2020). Evolocumab in HIV-Infected Patients With Dyslipidemia Primary Results of the Randomized, Double-Blind BEIJERINCK Study. Journal of the american college of cardiology, 75( 20), 2570-2584. doi:10.1016/j.jacc.2020.03.025
NLM
Boccara F, Kumar PN, Caramelli B, Calmy A, Lopez JAG, Bray S, Cyrille M, Rosenson RS. Evolocumab in HIV-Infected Patients With Dyslipidemia Primary Results of the Randomized, Double-Blind BEIJERINCK Study [Internet]. Journal of the american college of cardiology. 2020 ; 75( 20): 2570-2584.[citado 2024 nov. 09 ] Available from: https://doi.org/10.1016/j.jacc.2020.03.025
Vancouver
Boccara F, Kumar PN, Caramelli B, Calmy A, Lopez JAG, Bray S, Cyrille M, Rosenson RS. Evolocumab in HIV-Infected Patients With Dyslipidemia Primary Results of the Randomized, Double-Blind BEIJERINCK Study [Internet]. Journal of the american college of cardiology. 2020 ; 75( 20): 2570-2584.[citado 2024 nov. 09 ] Available from: https://doi.org/10.1016/j.jacc.2020.03.025
Artigo de periodico
Rationale and design of the AFFIRM-AHF trial: a randomised, double-blind, placebo-controlled trial comparing the effect of intravenous ferric carboxymaltose on hospitalisations and mortality in iron-deficient patients admitted for acute heart failure (2019)
Ponikowski, Piotr; Kirwan, Bridget-Anne; Anker, Stefan D.; Dorobantu, Maria; Drozdz, Jaroslaw; Fabien, Vincent; Filippatos, Gerasimos; Haboubi, Teba; Keren, Andre; Nicolau, José Carlos
Source: European journal of heart failure. Unidade: FM
Subjects: INSUFICIÊNCIA CARDÍACA, DOENÇAS NUTRICIONAIS E METABÓLICAS, FERRO, COMPOSTOS INORGÂNICOS, HOSPITALIZAÇÃO, ENSAIO CLÍNICO CONTROLADO RANDOMIZADO, RESULTADO DE TRATAMENTO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PONIKOWSKI, Piotr et al. Rationale and design of the AFFIRM-AHF trial: a randomised, double-blind, placebo-controlled trial comparing the effect of intravenous ferric carboxymaltose on hospitalisations and mortality in iron-deficient patients admitted for acute heart failure. European journal of heart failure, v. 21, n. 12, p. 1651-1658, 2019Tradução . . Disponível em: https://doi.org/10.1002/ejhf.1710. Acesso em: 09 nov. 2024.
APA
Ponikowski, P., Kirwan, B. -A., Anker, S. D., Dorobantu, M., Drozdz, J., Fabien, V., et al. (2019). Rationale and design of the AFFIRM-AHF trial: a randomised, double-blind, placebo-controlled trial comparing the effect of intravenous ferric carboxymaltose on hospitalisations and mortality in iron-deficient patients admitted for acute heart failure. European journal of heart failure, 21( 12), 1651-1658. doi:10.1002/ejhf.1710
NLM
Ponikowski P, Kirwan B-A, Anker SD, Dorobantu M, Drozdz J, Fabien V, Filippatos G, Haboubi T, Keren A, Nicolau JC. Rationale and design of the AFFIRM-AHF trial: a randomised, double-blind, placebo-controlled trial comparing the effect of intravenous ferric carboxymaltose on hospitalisations and mortality in iron-deficient patients admitted for acute heart failure [Internet]. European journal of heart failure. 2019 ; 21( 12): 1651-1658.[citado 2024 nov. 09 ] Available from: https://doi.org/10.1002/ejhf.1710
Vancouver
Ponikowski P, Kirwan B-A, Anker SD, Dorobantu M, Drozdz J, Fabien V, Filippatos G, Haboubi T, Keren A, Nicolau JC. Rationale and design of the AFFIRM-AHF trial: a randomised, double-blind, placebo-controlled trial comparing the effect of intravenous ferric carboxymaltose on hospitalisations and mortality in iron-deficient patients admitted for acute heart failure [Internet]. European journal of heart failure. 2019 ; 21( 12): 1651-1658.[citado 2024 nov. 09 ] Available from: https://doi.org/10.1002/ejhf.1710
Artigo de periodico
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction (2019)
Mcmurray, J. J. V; Solomon, S. D; Inzucchi, S. E; Kober, L; Kosiborod, M. N; Martinez, F. A; Ponikowski, P; Sabatine, M. S; Anand, I. S; Nicolau, José Carlos
Source: New england journal of medicine. Unidade: FM
Subjects: INSUFICIÊNCIA CARDÍACA, DIABETES MELLITUS NÃO INSULINO-DEPENDENTE, PROTEÍNAS DE TRANSPORTE, RESULTADO DE TRATAMENTO, ESTUDOS PROSPECTIVOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MCMURRAY, J. J. V et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. New england journal of medicine, v. 381, n. 21, p. 1995-2008, 2019Tradução . . Disponível em: https://doi.org/10.1056/NEJMoa1911303. Acesso em: 09 nov. 2024.
APA
Mcmurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Kober, L., Kosiborod, M. N., Martinez, F. A., et al. (2019). Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. New england journal of medicine, 381( 21), 1995-2008. doi:10.1056/NEJMoa1911303
NLM
Mcmurray JJV, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Nicolau JC. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction [Internet]. New england journal of medicine. 2019 ; 381( 21): 1995-2008.[citado 2024 nov. 09 ] Available from: https://doi.org/10.1056/NEJMoa1911303
Vancouver
Mcmurray JJV, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Nicolau JC. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction [Internet]. New england journal of medicine. 2019 ; 381( 21): 1995-2008.[citado 2024 nov. 09 ] Available from: https://doi.org/10.1056/NEJMoa1911303

USP Schools

ReP

Filtros

Authors

USP affiliated authors

Subjects

Source title

Funding Agencies